Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Cypherpunk Technologies Inc CYPH

Healthcare Biotechnology
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops... see more

Recent & Breaking News (NDAQ:CYPH)

Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)

Canada NewsWire 2 hours ago

Cypherpunk Adds Arjun Khemani as Strategic Advisor

Canada NewsWire January 22, 2026

Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC

Canada NewsWire December 30, 2025

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

Canada NewsWire December 19, 2025

Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor

Canada NewsWire December 9, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cypherpunk Technologies Inc. (NASDAQ: CYPH)

PR Newswire November 20, 2025

Cypherpunk Purchases Additional $18 Million of ZEC, Bringing Total Network Percentage to 1.43%

PR Newswire November 18, 2025

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

PR Newswire November 12, 2025

Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

PR Newswire November 12, 2025

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

PR Newswire October 20, 2025

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

PR Newswire October 9, 2025

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

PR Newswire October 6, 2025

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

PR Newswire September 25, 2025

Leap Therapeutics Reports Second Quarter 2025 Financial Results

PR Newswire August 14, 2025

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

PR Newswire June 23, 2025

Leap Therapeutics Reports First Quarter 2025 Financial Results

PR Newswire May 13, 2025

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

PR Newswire April 25, 2025

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

PR Newswire April 15, 2025

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

PR Newswire March 26, 2025

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

PR Newswire March 26, 2025

Podcasts